Phytate Inhibiting Calcium Salt Dissolution for Osteoporosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis primarily focus on preventing bone loss rather than stabilizing existing calcium salts, and there is a lack of effective substances that inhibit the dissolution of already formed calcium crystals, which is crucial in managing the condition.
Innovation Solution
Phytate (myo-inositol hexaphosphate) is used as an inhibitor to prevent the dissolution of calcium salts, particularly calcium phosphate, through its high affinity for calcium ions, adsorbing onto crystal surfaces to stabilize and prevent further dissolution, thereby treating and preventing osteoporosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments focus on preventing bone loss, then bone mass can be maintained to some extent, but they fail to stabilize already formed calcium salts and prevent their dissolution
Solution Approach 1:
The patent introduces citrate as an intermediary substance that mediates between calcium salts and the physiological environment. Citrate adsorbs onto the surface of calcium phosphate crystals, forming a protective layer that prevents dissolution without interfering with normal physiological processes. This intermediary action stabilizes existing bone mineral while maintaining biological compatibility.
Solution Approach 2:
The invention changes the chemical parameters at the crystal surface by introducing citrate ions that alter the surface charge and composition. This parameter change creates a more stable interface between the calcium phosphate crystals and surrounding fluids, reducing dissolution rates while maintaining the structural integrity of bone tissue.
2Object-affected harmful factors
If phytate is used to inhibit crystallisation of calcium salts, then pathological calcifications are prevented, but its ability to stabilize already formed crystals and prevent dissolution is not utilized
Solution Approach 1:
The patent inverts the conventional understanding of phytate's role. Instead of viewing it solely as a crystallization inhibitor that prevents formation, the invention demonstrates and utilizes its complementary function as a dissolution inhibitor that stabilizes existing crystals. This inverted perspective reveals a previously underutilized therapeutic mechanism for osteoporosis treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Phytate effectively inhibits the dissolution of calcium phosphate crystals, as demonstrated by its ability to adsorb and stabilize hydroxyapatite, leading to increased bone mass and reduced fracture risk, making it a promising treatment for osteoporosis.
Implementation Method 1
it shows a high affinity for divalent and trivalent metallic ions, such as calcium. It is precisely this affinity for calcium that leads to its property of inhibition of crystallisation of calcium salts, due to its high ability to adsorb on to surface of nuclei in formation or growing crystals
Data Source
Figure 1~2
AI summary
The present invention relates to the utilisation of myo-inositol hexaphosphate or pharmaceutically-acceptable salts thereof for the manufacture of a medicament destined for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. Said compound may be utilised in the manufacture of functional foods, dietetic complements, vitamin complements or nutritional complements or food complements or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.